Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles

International Journal of Cancer

Volumn 67, Issue 5, 1996, Pages 595-602

  Odunsi, Kunle ^a   Terry, George ^b   Linda, H O ^b   Bell, John ^a   Cuzick, Jack ^c   Ganesan, Trivadi S ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; HLA DQ ANTIGEN; HLA DR ANTIGEN;

ALLELE; ARTICLE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPILLOMA VIRUS; PRIORITY JOURNAL; UTERINE CERVIX DYSPLASIA;

ALLELES; BASE SEQUENCE; CERVICAL INTRAEPITHELIAL NEOPLASIA; DISEASE SUSCEPTIBILITY; DNA; FEMALE; HAPLOTYPES; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION;

EID: 0029770673     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960904)67:5<595::AID-IJC1>3.0.CO;2-P     Document Type: Article

References (31)

1. ANDERSON, M.C., BROWN, C.L., BUCKLEY, C., FOX, H., JENKINS, D., LOWE, D., MANNERS, B., MELCHER, D., ROBERTSON, A. and WELLS, M., Current views on cervical intraepithelial neoplasia. J. clin. Pathol., 44, 969-978 (1991).
2. APPLE, R.J., BECKER, T.M., WHEELER, C.M. and ERLICH, H.A., Comparison of human leukocyte antigen DR-DQ disease associations found with cervical dysplasia and invasive cervical carcinoma. J. nat. Cancer Inst., 87, 427-436 (1995).
3. ARMITAGE, P., Statistical methods in medical research, Blackwell, Oxford (1971).
4. BEGOVICH, A.B., MCCLURE, G.R., SURAJ, V.C., HELMUTH, R.C., FILDES, N., BUGAWAN, T.L., ERLICH, H.A. and KLITZ, W., Polymorphism, recombination, and linkage disequilibrium within the HLA class II region. J. Immunol., 148, 249-258 (1992).
5. BENTON, C., SHAHI-DULLAH, H. and HUNTER, J.A.A., HPV in the immunosuppressed. In: Papilloma virus report 3, pp. 23-26, Leeds University Press, Leeds (1992).
6. BRESLOW, N.E. and DAY, N.E., Statistical methods in cancer research: Vol. 1: The analysis of case control studies, IARC, Lyon (1980).
7. CHAMBERS, M., STACEY, S.N., ARRAND, J.R. and STANLEY, M.A., Delayed-type hypersensitivity response to human papillomavirus type 16 E6 protein in a mouse model. J. gen. Virol., 75, 165-169 (1994).
8. CHEN, L., THOMAS, E.K., HU, S.L., HELISTRÖM, J. and HELLSTRÖM, K.E., Human papillomavirus type 16 nucleoprotein E7 is a tumour rejection antigen. Proc. nat. Acad. Sci. (Wash.), 88, 110-114 (1991).
9. CHICZ, R. and URBAN, R., Analysis of MHC-presented peptides: applications in autoimmunity and vaccine development. Immunol. Today. 15, 155-160 (1994).
10. CUZICK, J., TERRY, G., HO, L., HOLLINGWORTH, T. and ANDERSON, M., Human papillomavirus type 16 in cervical smears as predictor of high-grade cervical intraepithelial neoplasia. Lancet, 339, 959-960 (1992).
11. CUZICK, J., TERRY, G., HO, L., HOLLINGWORTH, T. and ANDERSON, M., Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. Brit. J. Cancer, 69, 167-271 (1994).
12. DOHERTY, D.G., VAUGHAN, R.W., DONALDSON, P.T. and MOWAT, A.P., HLA DQA, DQB and DRB genotyping by oligonucleotide analysis: distribution of alleles and haplotypes in British Caucasoids. Hum. Immunol., 34, 53-63 (1992).
13. ELLIS, J.R.M., KEATING, P.J., BAIRD, J., HOUNSELL, E.F., RENOUF, D.V., ROWE, M., HOPKINS, D., DUGGAN-KEEN, M.F., BARTHOLOMEW, J.S., YOUNG, L.S. and STERN, P.L., The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nature (Med.), 1, 464-470 (1995).
14. FELTKAMP, M.C.W., SMITS, H.L., VIERBOOM, R.P., MINNAAR, R.P., DE JONGH, B.M., DRIJFHOUT, J.W., TER SCHEGGET, J., MELEIF, C.J.M. and KAST, W.M., Vaccination with cytotoxic T cell epitope-containing peptide protects against a tumour induced by human papillomavirus type 16-transformed cells. Europ. J. Immunol., 23, 22-42 (1993).
15. GAO, L., CHAIN, B., SINCLAIR, C., CRAWFORD, L., ZHOU, J., MORRIS, J., ZHU, X. and STAUSS, H., Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector. J. gen. Virol., 75, 157-164 (1994).
16. GLEW, S.S., DUGGAN, K.M., GHOSH, A.K., IVINSON, A., SINNOTT, P., DAVIDSON, J., DYER, P.A. and STERN, P.L., Lack of association of HLA polymorphisms with human papillomavirus-related cervical cancer. Hum. Immunol., 37, 157-164 (1993).
17. HILL, A.V., ELVIN, J., WILLIS, A.C., AIDOO, M., ALLSOPP, C.E., GOTCH, F.M., GAO, X.M., TAKIGUCHI, M., GREENWOOD, B.M., TOWNSEND, A.R., MCMICHAEL, A.J. and WHITTLE, H.C., Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature (Lond.), 360, 434-439 (1992).
18. KAST, W., BRANDT, R., SIDNEY, J., DRIJFHOUT, J., KUBO, R., GREY, H., MELEIF, C. and SETTE, A., Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J. Immunol., 3904-3912 (1994).
19. KIMURA, A. and SASAZUKI, T., Eleventh International Histocompatibility Workshop reference protocol for the HLA DNA-typing technique. In: K. Tsuji, M. Aizawa and T. Sasazuki (eds.), HLA 1991. Vol. 1, pp. 397-419, Oxford University Press, Oxford (1992).
20. KIVIAT, N., CRITCHLOW, C. and KURMAN, R., Reassessment of the morphological continuum of cervical intra-epithelial lesions: does it reflect different stages in the progression to cervical carcinoma? In: N. Muñoz, F.X. Bosch, K.V. Shah and A. Meheus (eds.), Epidemiology of cervical cancer and papillomaviruses, pp. 59-66, IARC, Lyon (1992).
21. MORRISON, E.A., HO, G.Y., VERMUND, S.H., GOLDBERG, G.L., KADISH, A.S., KELLEY, K.F. and BURK, R.D., Human papillomavirus infection and other risk factors for cervical neoplasia: a case-control study. Int. J. Cancer, 49, 6-13 (1991).
22. ODUNSI, K., TERRY, G., HO, L., BELL, J., CUZICK, J. and GANESAN, T.S., Association between HLA DQB1-asterisk-03 and cervical intraepithelial neoplasia. Mol. Med., 1, 161-171 (1995).
23. PARKIN, D.M., LAARA, E. and MUIR, C.S., Estimates of the worldwide frequency of sixteen major cancers in 1980. Int. J. Cancer, 41, 184-197 (1988).
24. SCHAFER, A., FRIEMANN, W., MIELKE, M., SCHWATLANDER, B. and KOCH, M.A., The increased frequency of cervical dysplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. Amer. J. Obstet. Gynaecol., 164, 593-599 (1991).
25. SCHIFFMAN, M.H., BAUER, H.M., HOOVER, R.N., GLASS, A.G., CADELL, D.M., RUSH, B.B., SCOTT, D.R., SHERMAN, M.E., KURMAN, R.J., WACHOLDER, S., STANTON, C.K. and MANOS, M.M., Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasm. J. nat. Cancer Inst., 85, 958-964 (1993).
26. SCHNEIDER, A. and KOUTSKY, L., Natural history and epidemiological features of genital HPV infection. In: M. Muñoz, F.X. Bosch, K.V. Shah and A. Meheus (eds.), The epidemiology of cervical cancer and human papillomavirus, pp. 23-53, IARC, Lyon (1992).
27. SILLMAN, F.H. and SEDLIS, A., Anogenital papillomavirus infection and neoplasia in immunodeficient women. In: R. Reed (ed.), Human papillomavirus, pp. 537-558, W.B. Saunders, Philadelphia (1987).
28. STERN, L.J., BROWN, J.H., JARDETZKY, T.S., GORGA, J.C., URBAN, R.G., STROMINGER, J.L. and WILEY, D.C., Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature (Lond.), 368, 215-221 (1994).
29. STRANG, G., HICKLING, J.K., MCINDOE, G.A., HOWLAND, K., WILKINSON, D., IKEDA, H. and ROTHBARD, J.B., Human T cell responses to human papillomavirus type 16 L1 and E6 synthetic peptides: identification of T cell determinants, HLA-DR restriction and virus type specificity. J. Gen. Virol., 71, 423-431 (1990).
30. TOMMASINO, M. and CRAWFORD, L., Human papillomavirus E6 and E7: proteins which deregulate the cell cycle. Bioessays, 17, 509-518 (1995).
31. WANK, R. and THOMSSEN, C., High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3. Nature (Lond.), 352, 723-725 (1991).